

Special Issue

Clinical and Translational Research of Urological Cancer

Message from the Guest Editors

It is our pleasure to invite you to collaborate on this Special Issue, 'Clinical and Translational Research of Urological Cancer'. The field of urological cancer is constantly evolving with new technologies, new therapeutic agents, and biomarkers with better perspectives for patients and urologists. The aim of this Issue is to give a panoramic view of the novelties and most recent, relevant evidence in the field of clinical and translational research of urological cancers, from the application of artificial intelligence to predict oncological outcomes to the new biomarkers and promising immunotherapy that have completely changed how urological cancers are managed. Original studies and reviews are more than welcome for this Issue to help increase our knowledge in the wide field of urological cancers.

Guest Editors

Dr. Mauro Ragonese

Department of Urology, Fondazione Policlinico Universitario Agostino Gemelli, IRCCS, 00168 Rome, Italy

Dr. Luca Di Gianfrancesco

Department of Urology, Humanitas Gavazzeni, Bergamo, Italy

Deadline for manuscript submissions

31 May 2026



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/240100

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)